

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
19 June 2025 (19.06.2025)



(10) International Publication Number  
**WO 2025/129126 A1**

(51) International Patent Classification:

*C07D 471/04* (2006.01) *A61P 29/00* (2006.01)  
*A61K 9/00* (2006.01) *C07D 401/06* (2006.01)  
*A61P 25/04* (2006.01)

(21) International Application Number:

PCT/US2024/060214

(22) International Filing Date:

13 December 2024 (13.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,218 14 December 2023 (14.12.2023) US

(71) Applicant: VM THERAPEUTICS LLC [US/US]; 47460 Fremont Blvd, Fremont, California 94538 (US).

(72) Inventors: WU, Jay Jie-Qiang; c/o VM Therapeutics LLC, 47460 Fremont Blvd, Fremont, California 94538 (US). WANG, Ling; c/o VM Therapeutics LLC, 47460 Fremont Blvd, Fremont, California 94538 (US).

(74) Agent: HOLLY, David C. et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))

(54) Title: TOPICAL FORMULATIONS OF CALCIUM CHANNEL BLOCKERS



("Compound 1")



("Compound 2");

(57) Abstract: The present disclosure relates to topical pharmaceutical compositions comprising 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (or 3-(2-(4-(4-fluorophenyl)(hydroxy)methyl)piperidin-1-yl)ethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one) or a pharmaceutically acceptable salt thereof, ("Compound 1") or ("Compound 2"); for the treatment of pain.

WO 2025/129126 A1